Stack WA - Search Results

1

Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease.

Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, Holmes G, Long R, Forbes A, Kamm MA. Stack WA, et al. Lancet. 1997 Feb 22;349(9051):521-4. doi: 10.1016/s0140-6736(97)80083-9. Lancet. 1997. PMID: 9048788 Clinical Trial.

2

Short- and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis.

Stack WA, Long RG, Hawkey CJ. Stack WA, et al. Aliment Pharmacol Ther. 1998 Oct;12(10):973-8. doi: 10.1046/j.1365-2036.1998.00396.x. Aliment Pharmacol Ther. 1998. PMID: 9798801 Clinical Trial.

3

Lack of effectiveness of the platelet-activating factor antagonist SR27417A in patients with active ulcerative colitis: a randomized controlled trial. The Platelet Activating Factor Antagonist Study Group in Ulcerative Colitis.

Stack WA, Jenkins D, Vivet P, Hawkey CJ. Stack WA, et al. Gastroenterology. 1998 Dec;115(6):1340-5. doi: 10.1016/s0016-5085(98)70011-3. Gastroenterology. 1998. PMID: 9834260 Clinical Trial.

4

Specific mediator-directed therapy for gastrointestinal diseases.

Stack WA, Hawkey CJ. Stack WA, et al. Eur J Gastroenterol Hepatol. 1997 Nov;9(11):1056-61. doi: 10.1097/00042737-199711000-00006. Eur J Gastroenterol Hepatol. 1997. PMID: 9431894 Review.

5

Novel treatments in inflammatory bowel disease.

Pathmakanthan S, Stack WA. Pathmakanthan S, et al. Among authors: stack wa. Hosp Med. 1999 Jan;60(1):19-23. doi: 10.12968/hosp.1999.60.1.1019. Hosp Med. 1999. PMID: 10197093 Review.

6

Impaired fatty-meal-stimulated gallbladder contractility in patients with Crohn's disease.

Murray FE, McNicholas M, Stack W, O'Donoghue DP. Murray FE, et al. Clin Sci (Lond). 1992 Dec;83(6):689-93. doi: 10.1042/cs0830689. Clin Sci (Lond). 1992. PMID: 1336439

7

Chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease.

Hawkey CJ, Stack WA. Hawkey CJ, et al. Among authors: stack wa. N Engl J Med. 1998 Jan 29;338(5):333-4. doi: 10.1056/nejm199801293380514. N Engl J Med. 1998. PMID: 9446034 No abstract available.

8

Protection against aspirin-induced human gastric mucosal injury by bosentan, a new endothelin-1 receptor antagonist.

Duggan AE, Stack W, Hull M, Filipowicz B, Knifton A, Crome R, Weber C, Bishop A, Polak J, Hawkey CJ. Duggan AE, et al. Aliment Pharmacol Ther. 1999 May;13(5):631-5. doi: 10.1046/j.1365-2036.1999.00516.x. Aliment Pharmacol Ther. 1999. PMID: 10233186 Clinical Trial.

9

Current pharmacotherapy for inflammatory bowel disease.

McKaig BC, Stack WA. McKaig BC, et al. Among authors: stack wa. Expert Opin Pharmacother. 1999 Nov;1(1):3-14. doi: 10.1517/14656566.1.1.3. Expert Opin Pharmacother. 1999. PMID: 11249561 Review.

10

Dose-dependent effects of ketoprofen on the human gastric mucosa in comparison with ibuprofen.

Donnelly MT, Richardson P, Hawkey CJ, Courtauld E, Stack WA. Donnelly MT, et al. Among authors: stack wa. Aliment Pharmacol Ther. 2000 May;14(5):543-9. doi: 10.1046/j.1365-2036.2000.00743.x. Aliment Pharmacol Ther. 2000. PMID: 10792116 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

28 results

Search Page

Filters